Autoimmune hepatitis (AIH) was the first liver disease for which an effective therapeutic intervention, corticosteroid treatment, was convincingly demonstrated in controlled clinical trials. However, 50 years later AIH still remains a major diagnostic and therapeutic challenge. There are two major reasons for this apparent contradiction: Firstly, AIH is a relatively rare disease. Secondly, AIH is a very heterogeneous disease.

Ces recommandations de l’EASL, en accès libre, concernant la prise en charge des hépatites auto-immunes seront bien utiles dans notre pratique.